A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON)

PI: Dr. ssa Claudia Proto 

The aim of this study is to find out whether the administration of savolitinib in combination with osimertinib can be an effective treatment for patients with NSCLC who have experienced disease progression while taking osimertinib as monotherapy. 

In summary, the study has four parts:  

1)Part 1 screening to confirm that your tumour is MET-positive. 

2)Part 2 of screening to confirm that you meet all the requirements to participate in the main study. 

3)Treatment period: 2 arms  

• Savolitinib + Osimertinib 
• Chemotherapy 

4)Follow up